U.S. Uterine Fibroids Treatment Devices Market Growth, Size, Trends Analysis - By Technology, By Mode of Treatment - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

U.S. Uterine Fibroids Treatment Devices Market Introduction and Overview

According to SPER market research, 'U.S. Uterine Fibroids Treatment Devices Market Growth, Size, Trends Analysis - By Technology, By Mode of Treatment - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the U.S. Uterine Fibroids Treatment Devices Market is predicted to reach 7.27 billion by 2034 with a CAGR of 9.52%.

Uterine fibroid treatment devices are medical tools utilized to reduce or eliminate non-cancerous growths in the uterus, referred to as fibroids. These devices provide minimally invasive alternatives to traditional surgical methods. Examples include instruments for uterine fibroid embolization (UFE), which obstruct the blood flow to fibroids, leading to their shrinkage. Others utilize focused ultrasound or radiofrequency ablation to heat and destroy fibroid tissue.

Restraints: Advanced treatment devices such as magnetic resonance-guided focused ultrasound (MRgFUS), robotic-assisted surgical systems, and radiofrequency ablation (RFA) devices demand sophisticated technology, leading to elevated manufacturing and acquisition costs. These devices are comprised of precision-engineered components, high-intensity imaging systems, and AI-driven controls, rendering them considerably more costly than conventional surgical instruments.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Technology, By Mode of Treatment

Regions covered Northeast, Midwest, West, South

Companies Covered Medtronic, Stryker, Boston Scientific Corporation, Insightec, CooperSurgical Inc, Hologic, Inc, CONMED Corporation, Merit Medical Systems, Minerva Surgical, Inc.

U.S. Uterine Fibroids Treatment Devices Market Segmentation:

By Technology: Based on the Technology, U.S. Uterine Fibroids Treatment Devices Market is segmented as; Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques.

By Mode of Treatment: Based on the Mode of Treatment, U.S. Uterine Fibroids Treatment Devices Market is segmented as; Invasive Treatment, Minimally Invasive Treatment, Non-invasive Treatment.

By Region: This research also includes data for Northeast, Midwest, West, South.

Product Code: HLCA25304

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. U.S. Uterine Fibroids Treatment Devices Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in U.S. Uterine Fibroids Treatment Devices Market

7. U.S. Uterine Fibroids Treatment Devices Market, By Technology (USD Million) 2021-2034

7.1. Surgical Techniques
- 7.1.1. Hysterectomy
- 7.1.2. Myomectomy
7.2. Laparoscopic Techniques
- 7.2.1. Laparoscopic Myomectomy
- 7.2.2. Myolysis
7.3. Ablation Techniques
- 7.3.1. Microwave Ablation
- 7.3.2. Hydrothermal Ablation
- 7.3.3. Cryoablation
- 7.3.4. Ultrasound Ablation
7.4. Embolization Techniques

8. U.S. Uterine Fibroids Treatment Devices Market, By Mode of Treatment (USD Million) 2021-2034

8.1. Invasive Treatment
8.2. Minimally Invasive Treatment
8.3. Non-invasive Treatment

9. U.S. Uterine Fibroids Treatment Devices Market, (USD Million) 2021-2034

9.1. U.S. Uterine Fibroids Treatment Devices Market Size and Market Share

10. U.S. Uterine Fibroids Treatment Devices Market, By Region, (USD Million) 2021-2034

10.1. Northeast
10.2. Midwest
10.3. West
10.4. South

11. Company Profile

11.1. Medtronic
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
11.2. Stryker
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
11.3. Boston Scientific Corporation
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
11.4. Insightec
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
11.5. CooperSurgical Inc
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
11.6. Hologic, Inc
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
11.7. CONMED Corporation
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
11.8. Merit Medical Systems
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
11.9. Minerva Surgical, Inc
- 11.9.1. Company details
- 11.9.2. Financial outlook
- 11.9.3. Product summary
- 11.9.4. Recent developments
11.10. Others